Comparar lenalidomida y daratumumab subcutáneo versus lenalidomida y dexametasona en sujetos frágiles con mieloma múltiple no tratado previamente que no son elegibles para terapia de dosis alta (IFM2017_03)
Un estudio de fase III que compara lenalidomida y daratumumab subcutáneo (R-Dara SC) versus lenalidomida y dexametasona (Rd) en sujetos frágiles con mieloma múltiple no tratado previamente que no son elegibles para terapia de dosis alta
This is a Phase 3, randomized (study drug assigned by chance), open-label (participants and researchers are aware about the treatment, participants are receiving), active-controlled (study in which the experimental treatment or procedure is compared to a standard treatment or procedure), parallel-group (each group of participants will be treated at the same time), and multicenter (when more than one hospital team work on a medical research study) study in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) and who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT). The primary hypothesis of this study is that subcutaneous Daratumumab in combination with Lenalidomide will prolong progression-free survival and likely induce less toxicity as compared with Lenalidomide and dexamethasone, in elderly frail subjects with newly diagnosed Multiple myeloma who are ineligible for high dose chemotherapy and ASCT
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The primary hypothesis of this study is that subcutaneous Daratumumab in combination with Lenalidomide will prolong progression-free survival and likely induce less toxicity as compared with Lenalidomide and dexamethasone, in elderly frail subjects with newly diagnosed Multiple myeloma who are ineligible for high dose chemotherapy and ASCT
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Besançon, Francia
- Chru Jean Minjoz
-
Blois, Francia
- Ch Blois Simone Veil
-
Bourg-en-Bresse, Francia
- Ch Fleyriat
-
Brest, Francia
- Chru Brest Site Hopital Morvan
-
Caen, Francia
- Chu de Caen Normandie
-
Cesson-Sévigné, Francia
- Hopital Prive Sevigne - Cesson
-
Dijon, Francia
- Chu Dijon Bourgogne
-
Grenoble, Francia
- Chu de Grenoble
-
La Rochelle, Francia
- Gpe Hospitalier La Rochelle-Re-Aunis
-
Le Coudray, Francia
- Ch Chartres Louis Pasteur-Le Coudray
-
Lille, Francia
- Hôpital Claude Huriez, CHU
-
Marseille, Francia
- Institut Paoli Calmettes
-
Mont-de-Marsan, Francia
- Chi Mont de Marsan Et Pays Des Sources
-
Montpellier, Francia
- Chu Montpellier
-
Nantes, Francia
- Chu de Nantes Site Hotel Dieu Hme
-
Nice, Francia
- Chu de Nice Hopital de L'Archet
-
Pessac, Francia, 33604
- Hopital Haut-Leveque - Chu
-
Périgueux, Francia
- Centre Hospitalier de Perigueux
-
Rennes, Francia
- Chru Rennes Site Pontchaillou
-
Saint-Quentin, Francia
- Centre Hospitalier de Saint Quentin
-
St-Malo, Francia
- Centre Hospitalier Saint-Malo
-
Toulouse, Francia
- Oncopole Chu Toulouse
-
Tours, Francia
- Chu de Tours
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Subject must be at least 65 years of age.
-
Subject must have documented multiple myeloma satisfying the CRAB criteria and measurable disease.
-
Newly diagnosed and not considered candidate for high-dose chemotherapy with SCT.
-
Subject must have a Frailty Score ≥ 2
-
Subject must have within 5 days prior to first drug intake (C1D1) pretreatment clinical laboratory values meeting the following criteria during the Screening Phase:
- hemoglobin ≥7.5 g/dL
- absolute neutrophil count ≥1.0 x 109/L
- platelet count ≥70 x 109/L
- aspartate aminotransferase (AST) ≤2.5 x upper limit of normal (ULN)
- alanine aminotransferase (ALT) ≤2.5 x ULN
- total bilirubin ≤2.0 x ULN
- creatinine clearance≥30mL/min
-
Measurable ISS with β2-microglobulin and albumin values for randomization
-
A man who is sexually active with a woman of childbearing potential must agree to use a latex or synthetic condom, even if they had a successful vasectomy. All men must also not donate sperm during the study, for 4 weeks after the last dose of lenalidomide, and for 4 months after the last dose of daratumumab. Women participating in this study must be postmenopausal.
-
Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol, as referenced in the ICF.
-
Subjects affiliated with an appropriate social security system.
Exclusion Criteria:
-
Subject has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma.
-
Subject has a diagnosis of Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
-
Subject has prior or current systemic therapy or SCT for multiple myeloma
-
Subject has a history of malignancy (other than multiple myeloma) within 5 years before the date of randomization
-
Subject has had radiation therapy within 14 days of randomization.
-
Subject has had plasmapheresis within 28 days of randomization.
-
Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma.
-
Subject has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume [FEV] in 1 second <60% of predicted normal), persistent asthma, or a history of asthma within the last 2 years (intermittent asthma is allowed).
-
Subject is known to be seropositive for history of human immunodeficiency virus (HIV)
-
Seropositive for hepatitis B.
-
(Known to be) seropositive for hepatitis C
-
Subject has any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study.
-
Subject has clinically significant cardiac disease, including:
- myocardial infarction within 1 year before randomization, or an unstable or uncontrolled disease/condition related to or affecting cardiac function
- uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities
- screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec
-
Subject has known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients
-
Subject has plasma cell leukemia or POEMS syndrome
-
Subject is known or suspected of not being able to comply with the study protocol. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject or that could prevent, limit, or confound the protocol-specified assessments.
-
Subject has had major surgery within 2 weeks before randomization or has not fully recovered from surgery.
-
Subject has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 4 weeks before randomization or is currently enrolled in an interventional investigational study.
-
Refusal to consent or protected by legal regime ( guardianship, trusteeship)
-
Subject has contraindications to required prophylaxis for deep vein thrombosis and pulmonary embolism
-
Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm 1: Experimental group
Daratumumab SC 1800 mg
|
Daratumumab SC 1800 mg
Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression |
|
Comparador falso: Arm 2: Control group
Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression |
Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
The primary objective is to compare the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) to that of Lenalidomide and Dexamethasone (Rd), in terms of PFS in frail subjects with newly diagnosed myeloma who are not candidates for high dose chemotherapy and autologous stem cell transplant. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Fracaso del tiempo hasta el tratamiento
Periodo de tiempo: Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
|
|
Tiempo hasta el próximo tratamiento
Periodo de tiempo: Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
|
|
Tiempo de SLP2
Periodo de tiempo: Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
|
|
Supervivencia libre de eventos
Periodo de tiempo: Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
Desde la fecha de aleatorización hasta la fecha de la primera progresión documentada o la fecha de toxicidad o la fecha de muerte por cualquier causa, lo que ocurra primero, evaluado hasta 84 meses
|
|
|
Overall survival (OS) time
Periodo de tiempo: From date of randomization until the date of death from any cause, whichever came first, assessed up to 84months
|
Overall survival (OS) time, |
From date of randomization until the date of death from any cause, whichever came first, assessed up to 84months
|
|
Complete remission (CR)
Periodo de tiempo: From date of randomization until the date of first documented progression whichever came first, assessed up to 84months
|
Percentage of participants with CR, as defined by the IMWG criteria, will be reported. |
From date of randomization until the date of first documented progression whichever came first, assessed up to 84months
|
|
Very good partial response (VGPR) or better.
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
VGPR or better, defined as VGPR or CR according to the IMWG criteria during or after the study treatment at the time of data cutoff. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Overall response (CR + VGPR + partial response [PR]).
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Overall response, defined as CR or VGPR or PR, according to the IMWG criteria |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Occurrence of grade 3 or more side effects.
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Collecting all AE (grade 3 or more) |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Safety and tolerability of Daratumumab SC when administered in combination with Revlimid: NCI-CTCAE V5.0.
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Evaluation of safety data by type, frequency, severity, relation to study drug, according to NCI-CTCAE V5.0. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Evaluation of quality of life based on MY20 questionnaires
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Treatment effects on patient reported outcomes and heath economic/resource utilization. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Evaluation of quality of life based on EORTC C30 questionnaires
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Treatment effects on patient reported outcomes and heath economic/resource utilization. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Evaluation of quality of life based on EQ-5D questionnaires
Periodo de tiempo: From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
Treatment effects on patient reported outcomes and heath economic/resource utilization. |
From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months
|
|
Minimal residual disease (MRD) negative rate at 12 months.
Periodo de tiempo: after 12 months of treatment
|
Proportion of participants assessed as MRD negative |
after 12 months of treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thierry Facon, MD,PhD, University Hospital, Lille
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Neoplasias
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Enfermedades hemic y linfáticas
- Mieloma múltiple
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Ácidos carboxílicos
- Piperidinas
- Ftalimidas
- Ácidos ftálicos
- Ácidos, carbocíclicos
- Piperidonas
- Isoindoles
- Lenalidomida
Otros números de identificación del estudio
- 2018_16
- 2018 (Subvención/contrato del NIH de EE. UU.)
- 2018-003535-30 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .